Your session is about to expire
← Back to Search
Pembrolizumab for T-Cell Lymphoma
Study Summary
This trial is testing brentuximab vedotin + pembrolizumab to see if it's more effective than brentuximab vedotin alone for treating patients with recurrent peripheral T-cell lymphoma.
- T-Cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Follicular T-Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Subcutaneous Panniculitis-Like T-Cell Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have Hepatosplenic T-cell lymphoma (HSTCL).You have a type of lymphoma called peripheral T-cell lymphoma, not otherwise specified.You have a type of lymphoma known as subcutaneous panniculitis-like T-cell lymphoma.You have a type of lymphoma called Angioimmunoblastic T-cell lymphoma (AITL).You have adult T-cell leukemia/lymphoma (ATLL) or cutaneous T-cell lymphoma (CTCL).You have Enteropathy-associated T-cell lymphoma (EATL).You have a type of lymphoma called peripheral T-cell lymphoma with a T-follicular helper phenotype that affects your lymph nodes.You have been treated with drugs that affect the immune system in a similar way to the study drug.You have had pancreatitis in the past.You have moderate to severe nerve damage in your hands or feet before the study starts.You have a history of lung disease that caused inflammation and required treatment with steroids, or you currently have lung inflammation.You have a medical condition that is not being managed correctly.Your cancer has come back after treatment and it has been more than 6 months since your first treatment. Or, your cancer has come back after secondary/subsequent treatments. However, if your cancer has come back within 6 months of your first treatment, you cannot participate. If you have received brentuximab vedotin or immunotherapy before, you may also be excluded.You have received treatment for your disease in the past, but it has come back or has not responded well to the treatment.You have a type of lymphoma called Follicular T-cell lymphoma (FTCL).You have a specific type of lymphoma called Extranodal Natural Killer/T-cell Lymphoma (ENKTL).You have a rare type of lymphoma called Anaplastic Large Cell Lymphoma (ALCL) and your cancer cells express a protein called CD30.
- Group 1: Treatment (brentuximab vedotin, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participation in this experiment?
"Affirmative. According to the information hosted on clinicaltrials.gov, this experiment is actively recruiting participants since its debut on March 1st 2020 and most recent update in June 15th 2022. 40 volunteers need to be sourced from a single site for the trial's completion."
What potential hazards exist when utilizing Brentuximab Vedotin?
"Brentuximab Vedotin was assessed as a 2 on the safety scale, due to there being only data supporting its security in Phase 2 trials with no existing evidence of efficacy."
How is Brentuximab Vedotin typically employed to improve the wellbeing of patients?
"Brentuximab Vedotin is a viable therapy option for individuals with unresectable melanoma and similar conditions like microsatellite instability high, recurrent risk of disease, etc."
Are there any additional studies that have evaluated the efficacy of Brentuximab Vedotin?
"Currently, there are 1016 trials underway assessing the effectiveness of Brentuximab Vedotin. Of those studies, 127 are in Phase 3 and have been established at 37540 sites across America with many being based in Boston, Massachusetts."
Is this investigation currently open to enrollment?
"According to up-to-date information on clinicaltrials.gov, this trial is actively recruiting participants. It was initially posted on the 1st of March 2020 and has most recently been revised as of the 15th June 2022."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger